CD8A and neoplasm: The administration of ULNPs-cRNAIL-2F@G greatly activated the proliferation of CD8+ T cells, and the frequency of tumor-infiltrating CD8+ Ki67+ T cells reached 17.9% in mice treated with ULNPs-cRNAIL-2F@G, surpassing the frequencies observed in ULNPs-cRNAIL-2F (12.6%), CLNPs-cRNAIL-2F (12.4%), and IL-2F (8.4%) groups (Fig. 5J).